Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.47 |
| ▸ | HTR2B | P41595 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578499 | 0.86 | SIGMAR1 (0.53) | KMT2AMEN1SIGMAR1DRD2 | |
| SCHEMBL5578847 | 0.79 | MAPT (0.50) | KMT2AMEN1HTR2C | |
| SCHEMBL5254949 | 0.78 | KMT2A (1.00) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL5578652 | 0.78 | KMT2A (0.47) | KMT2AMEN1SIGMAR1HTR2AALDH1A1 | |
| SCHEMBL5578664 | 0.76 | DRD1 (0.41) | KMT2AMEN1SIGMAR1DRD2ALDH1A1 | |
| SCHEMBL18221709 | 0.76 | SIGMAR1 (0.67) | SIGMAR1OPRM1HTR2AHTR2CHTR2B | |
| SCHEMBL5578671 | 0.75 | KMT2A (0.36) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL5579027 | 0.74 | STS (0.48) | KMT2AMEN1 | |
| SCHEMBL18209386 | 0.72 | SIGMAR1 (0.59) | SIGMAR1OPRM1HTR2AHTR2CHTR2B | |
| SCHEMBL5578636 | 0.71 | SIGMAR1 (0.55) | SIGMAR1OPRM1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | claimed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | REN, AVPR2, RECQL | KMT2A 1940/4885MEN1 882/4885SIGMAR1 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.